Literature DB >> 23883226

Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy?

My-Linh Nguyen1, Debra A Gervais, Michael A Blake, Peter R Mueller, Dushyant V Sahani, Peter F Hahn, Raul N Uppot.   

Abstract

OBJECTIVE: The purpose of our study was to analyze the effect of lesion location and morphologic appearance on CT on the positive predictive value (PPV) for malignancy of all extrapulmonary lesions that were (18)F-FDG avid on PET/CT and that were biopsied under imaging guidance.
MATERIALS AND METHODS: Between January 2004 and December 2010, 227 patients underwent imaging-guided biopsy of 231 PET-positive extrapulmonary lesions with diagnostic pathologic results. The PET PPV for malignancy was retrospectively calculated and stratified according to lesion location and morphologic appearance.
RESULTS: The overall PET PPV for malignancy was 72%. Inflammatory processes accounted for the majority of benign biopsy results. Lesion location significantly affected the PPV (p < 0.001). Bone (96%) and liver (90%) lesions had significantly higher PPVs for malignancy compared with other locations, whereas lymph nodes (60%) had a significantly lower PPV for malignancy. Lesions that were morphologically suspicious and morphologically benign according to CT findings alone were associated with PPVs of 74% and 57%, respectively (p = 0.05). FDG-avid subcentimeter lymph nodes (n = 8) had a PPV for malignancy of 38%.
CONCLUSION: Over half of PET-avid morphologically benign-appearing lesions and one third of PET-avid subcentimeter lymph nodes were found to be malignant at biopsy, suggesting that benign morphologic appearance alone should not preclude further workup of a PET-positive lesion. Biopsies of FDG-avid lesions in liver and bone yielded high rates of true malignancy, whereas biopsies of lymph nodes yielded a lower rate of malignancy compared with other lesion locations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883226     DOI: 10.2214/AJR.12.9166

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

1.  Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.

Authors:  F Cornelis; M Silk; H Schoder; H Takaki; J C Durack; J P Erinjeri; C T Sofocleous; R H Siegelbaum; M Maybody; S B Solomon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-09       Impact factor: 9.236

2.  Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT.

Authors:  Hugo J A Adams; John M H de Klerk; Ben G F Heggelman; Stefan V Dubois; Thomas C Kwee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-04       Impact factor: 9.236

3.  The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population.

Authors:  Naila Loudini; Andor W J M Glaudemans; Paul C Jutte; Derya Yakar; Thomas C Kwee
Journal:  Skeletal Radiol       Date:  2020-04-06       Impact factor: 2.199

4.  Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma.

Authors:  Alessandro Broccoli; Cristina Nanni; Alberta Cappelli; Francesco Bacci; Alessandro Gasbarrini; Elena Tabacchi; Carlo Piovani; Lisa Argnani; Riccardo Ghermandi; Elena Sabattini; Rita Golfieri; Stefano Fanti; Pier Luigi Zinzani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-15       Impact factor: 9.236

5.  Evaluation of Radiation Exposure to the Patients Undergoing Positron Emission Tomography/Computed Tomography-Guided Biopsies.

Authors:  Krishnapriya Deva; Nivedita Rana; Rajender Kumar; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2022-03-25

6.  Clinical and FDG-PET/CT Suspicion of Malignant Disease: Is Biopsy Confirmation Still Necessary?

Authors:  Talitha Bent; Derya Yakar; Thomas C Kwee
Journal:  Diagnostics (Basel)       Date:  2021-03-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.